In:
Journal of Neuroscience Research, Wiley, Vol. 89, No. 1 ( 2011-01), p. 58-72
Abstract:
Neuronal noncytokine‐dependent p50/p65 nuclear factor‐κB (the primary NF‐κB complex in the brain) activation has been shown to exert neuroprotective actions. Thus neuronal activation of NF‐κB could represent a viable neuroprotective target. We have developed a cell‐based assay able to detect NF‐κB expression enhancement, and through its use we have identified small molecules able to up‐regulate NF‐κB expression and hence trigger its activation in neurons. We have successfully screened approximately 300,000 compounds and identified 1,647 active compounds. Cluster analysis of the structures within the hit population yielded 14 enriched chemical scaffolds. One high‐potency and chemically attractive representative of each of these 14 scaffolds and four singleton structures were selected for follow‐up. The experiments described here highlighted that seven compounds caused noncanonical long‐lasting NF‐κB activation in primary astrocytes. Molecular NF‐κB docking experiments indicate that compounds could be modulating NF‐κB‐induced NF‐κB expression via enhancement of NF‐κB binding to its own promoter. Prototype compounds increased p65 expression in neurons and caused its nuclear translocation without affecting the inhibitor of NF‐κB (I‐κB). One of the prototypical compounds caused a large reduction of glutamate‐induced neuronal death. In conclusion, we have provided evidence that we can use small molecules to activate p65 NF‐κB expression in neurons in a cytokine receptor‐independent manner, which results in both long‐lasting p65 NF‐κB translocation/activation and decreased glutamate neurotoxicity. © 2010 Wiley‐Liss, Inc.
Type of Medium:
Online Resource
ISSN:
0360-4012
,
1097-4547
Language:
English
Publisher:
Wiley
Publication Date:
2011
detail.hit.zdb_id:
1474904-X
detail.hit.zdb_id:
195324-2
SSG:
12
